Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation: A Patient Guide

Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation, or APLAID, is an exceedingly rare genetic condition that fundamentally changes how the immune system functions. In most people, the immune system is either working well or it is weakened. In APLAID, the immune system is “dysregulated,” meaning it struggles in two opposite directions: it can be hyperactive, causing inappropriate inflammation that can damage healthy tissue, while also being underactive, leaving the body vulnerable to infections ^[1]. This unique “dual nature” is caused by a specific mutation in the PLCG2 gene, which alters signaling pathways in various immune cells, flooding the body with confused defense signals ^[2].

The symptoms of APLAID typically begin in early infancy and can affect many parts of the body. Most patients deal with recurring inflammatory flares—such as blistering skin rashes, unexplained fevers, and painful joints—that occur without an underlying infection ^[3]. At the same time, this altered signaling disrupts the development of B cells and the production of antibodies (protective proteins). This leads to an antibody deficiency, making patients more likely to develop frequent or severe bacterial infections, particularly in the sinuses and lungs ^[1][4]. Because the condition is so rare—with literature reviews as of 2021 noting about 30 reported cases globally—every patient’s experience is unique, and symptoms can vary significantly from one person to the next ^[5].

Living with APLAID requires a highly individualized and multidisciplinary approach to care. Because the condition can affect multiple organ systems, including the skin, lungs, eyes, and (in a subset of reported patients) blood vessels, patients typically work with a team of specialists—such as immunologists, rheumatologists, and cardiologists—who coordinate to find the right balance of treatments ^[6]. Management often involves two main goals: using targeted therapies or anti-inflammatory medications to calm the internal flares, and using immunoglobulin replacement therapy or antibiotics to help the body fight off outside germs ^[1][4]. While the medical community is still learning about APLAID, the focus remains on proactive monitoring and tailored care to help each patient live as healthy and active a life as possible ^[5].

What is known and what is still uncertain?
Because APLAID is so rare, there are no universally established, large-scale clinical trials predicting the exact course of the disease or the perfect treatment protocol. The available evidence is based on a small number of reported cases. While the goals are clear—preventing organ damage, reducing flares, and treating infections—the specifics of each patient’s journey, including which complications they might face, remain highly variable.